Medical World News® Deep Dive: Expert Talks FDA Approval of Amivantamab to Treat NSCLC With EGFR Exon 20 Insertion Mutations
Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
In this episode of Deep Dive from the Medical World News® broadcast, CancerNetwork® spoke with Joshua Sabari, MD, of NYU Langone Health Perlmutter Cancer Center, to learn more about amivantamab (Rybrevant) as a treatment for non–small cell lung cancer with EGFR exon 20 insertion mutations.
Sabari detailed the challenges of treating tumors with this mutation and compared amivantamab with the other systemic therapy options in this setting. He also discusses what the future might have in store for amivantamab in this specific disease.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
